What is Movair?
Formerly operating as International Biophysics Corporation, Movair has cultivated over three decades of expertise in the development of respiratory care solutions. The company is widely recognized for its flagship product, the AffloVest, which provides high-frequency chest wall oscillation therapy, alongside the LUISA portable home ventilator. By bridging the gap between clinical requirements and patient-centric home care, Movair maintains a critical market position. Their focus remains on enhancing the quality of life for individuals suffering from chronic respiratory conditions through continuous, effortless breathing support and advanced treatment strategies.
How much funding has Movair raised?
Movair has raised a total of $988K across 2 funding rounds:
Debt
$350K
Debt
$638K
Debt (2020): $350K with participation from PPP
Debt (2021): $638K led by PPP
Key Investors in Movair
PPP
Public-Private Partnership
Undisclosed Investor
An institutional partner participating in the funding round to facilitate long-term growth and market expansion for Movair.
Undisclosed Investor
A strategic backer focused on the healthcare sector, providing the necessary financing to advance respiratory care innovation.
What's next for Movair?
With the recent capital infusion, Movair is positioned to accelerate its research and development pipeline, focusing on the next generation of respiratory technology. The strategic allocation of these funds will likely prioritize the expansion of their clinical footprint and the optimization of their supply chain to meet the growing demand for portable, home-based medical equipment. As the company transitions into this next phase of enterprise-level growth, stakeholders anticipate further integration of digital health monitoring and improved patient outcomes, solidifying Movair's role as a leader in the respiratory care ecosystem.
See full Movair company page
